Re: The 10Q-4 will be interesting to see how much sugar coating they do.
I wonder if it will include:
"We expect that research and development expenses will increase."
"We have no therapeutic products currently available for sale."
"We continue to repay our debt financing's in shares of common stock."
++++++++++++++++++++++++++++++++++++++++++++++++++
Thanks very much again, ddls, for keeping us apprised of these incredibly unique and revealing statements from the "Forward-Looking Statements" section. But you did neglect to include:
"limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally"
as well as:
"There can be no assurance that the Company’s clinical trials will be successful."
Yes, ddls, as you suggest and thanks for pointing out that any company worth it's salt should be able to guarantee in advance that the Company’s clinical trials will be successful and, thus, should be able to convince the FDA to skip the trials and approve their products post haste without delay.
Market Data 
Markets 
AI
